Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects
Funding for this research was provided by:
Heptares Therapeutics Ltd
Accepted: 28 May 2021
First Online: 23 June 2021
: This study was sponsored by Heptares Therapeutics Ltd.
: Jan Liptrot, Steve Dickinson and Tim Tasker are currently paid employees of Sosei Heptares and have owned stock in the company. David M. Cross is a paid independent consultant for Sosei Heptares.
: This study was approved by the medical ethics review board of the foundation Beoordeling Ethiek Biomedisch Onderzoek (BEBO, Assen, The Netherlands).
: All subjects provided informed consent before participation.
: Not applicable
: The datasets generated and/or analysed during the current study are filed in EudraCT and are not publicly available (in accordance with the regulations for phase I data). Further information is available from the corresponding author on reasonable request.
: The code that is used to model the data is available upon request.